British multinational pharmaceutical company GlaxoSmithKline (NYSE: GSK) declared in its last quarterly earnings call that the company’s integration and restructuring programs are on track, and sales are benefiting from recent new product introductions and most products recently acquired.So much so, that the company says it will meet its guidance for 2015… Read More

This telecom has a lot of potential in 2016. Read More

Not only do they have great yields, their prices are about to soar. Read More

The consequences of China’s currency gambit. Read More

The flight to safety means higher REIT prices and dividend income. Read More

We’re thankful we made good calls this year. Read More

With prices low and inventory high, the sector lacks the dividend pricing power we look for. Read More

A stronger U.S. dollar weighs down earnings. Read More

National Grid is moving to higher-growth businesses. Read More

This spirits maker continues growing both its earnings and dividends. Read More